news_6

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as...